Antibody Compositions And Methods Of Use Thereof
Patent No. EP4267105 (titled "Antibody Compositions And Methods Of Use Thereof") was filed by Bristol Myers Squibb on Dec 27, 2021. The application was issued on Mar 26, 2025.
Patent Summary
A pharmaceutical composition for treating tumors via subcutaneous administration comprises nivolumab at approximately 120 mg/mL or 150 mg/mL, 20 mM histidine, 250 mM sucrose, 0.05% w/v polysorbate 80, 50 µM pentetic acid, 5 mM methionine, and 2000 U/mL rHuPH20. The composition utilizes nivolumab as an anti-PD-1 antibody, rHuPH20 as an endoglycosidase hydrolase enzyme, and methionine as a sacrificial antioxidant. The formulation is designed for delivery via vials, syringes, auto-injectors, or wearable pumps to improve patient compliance over intravenous administration. The composition may be provided as a unit dose with a total volume of less than 5 mL, delivering an effective dose of 250 mg to 2400 mg of the antibody.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP4267105
- Application Number
- EP21851751A
- Filing Date
- Dec 27, 2021
- Status
- Granted And Under Opposition
- Feb 21, 2025
- Publication Date
- Mar 26, 2025
- External Links
- Slate, Register , Google Patents